In 2025, New York state and federal courts issued a series of consequential decisions shaping the litigation landscape for pharmaceutical, medical device, and other Food and Drug Administration (FDA)-regulated industries. Defense counsel must closely track these rulings, which continue to refine pleading standards, preemption, the learned intermediary doctrine, and class-action viability….
By: Harris Beach Murtha
By: Harris Beach Murtha
